Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 683 free, full-text research articles on human participants. First 3 results:

[Hematologic response predictor factors in adults with myelodysplastic syndromes (SMD) treated with cyclosporin A (CSA)].
 

Author(s): Elia Zamora-Pérez, Xavier López-Karpovitch

Journal: Gac Med Mex. ;151(3):345-53.

 

Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic cells. The International Prognostic Scoring System (IPSS) is the risk scale most employed in MDS. Cyclosporin A (CsA) has been used in the treatment of cytopenias in MDS.

Last Updated: 19 Jun 2015

Go To URL
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
 

Author(s): Chi Young Ok, Keyur P Patel, Guillermo Garcia-Manero, Mark J Routbort, Jie Peng, Guilin Tang, Maitrayee Goswami, Ken H Young, Rajesh Singh, L Jeffrey Medeiros, Hagop M Kantarjian, Rajyalakshmi Luthra, Sa A Wang

Journal:

 

TP53 mutation is more prevalent in therapy-related myeloid neoplasms (t-MN) than their de novo counterparts; however, the pattern of mutations involving TP53 gene in t-MN versus de novo diseases is largely unknown.

Last Updated: 14 May 2015

Go To URL
Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?
 

Author(s): Uwe Platzbecker, Pierre Fenaux

Journal: Haematologica. 2015 May;100(5):568-71.

 

Last Updated: 6 May 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 140 free, full-text review articles on human participants. First 3 results:

Established and novel agents for myelodysplastic syndromes.
 

Author(s): Mikkael A Sekeres, Aaron T Gerds

Journal: Hematology Am Soc Hematol Educ Program. 2014 Dec;2014(1):82-9.

 

The myelodysplastic syndromes (MDS) are the most commonly diagnosed myeloid malignancy, with >15 000 new cases identified in the United States yearly. Prognostic scoring systems supplant a formal staging approach and, in general, divide patients into those with lower-risk and those ...

Last Updated: 20 Feb 2015

Go To URL
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.
 

Author(s): Corey Cutler

Journal: Hematology Am Soc Hematol Educ Program. 2014 Dec;2014(1):77-81.

 

Allogeneic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) is a potentially curative procedure, but is associated with a significant risk of morbidity and mortality. With the recent approval of disease-modifying agents, the appropriate timing of allogeneic ...

Last Updated: 20 Feb 2015

Go To URL
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
 

Author(s): Hironori Harada, Yuka Harada

Journal: Cancer Sci.. 2015 Apr;106(4):329-36.

 

Myelodysplastic syndromes (MDS) are defined as stem cell disorders caused by various gene abnormalities. Recent analysis using next-generation sequencing has provided great advances in identifying relationships between gene mutations and clinical phenotypes of MDS. Gene mutations ...

Last Updated: 22 Apr 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome

 

Last Updated: 16 Oct 2015

Go to URL
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
 

Status: Not yet recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome

 

Last Updated: 16 Sep 2015

Go to URL
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome

 

Last Updated: 12 Jan 2016

Go to URL